Study Using PET/CT to Characterize the Effect of Reslizumab on Airway Inflammation

Study Title
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
Teva Identifier
C38072-AS-40105
ClinicalTrials.gov Identifier
NCT02937168
Study Status
Terminated
Trial Condition(s)
Asthma
Interventions
Drug: Reslizumab | Drug: Fludeoxyglucose F 18 (FDG) | Drug: Placebo
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Print

Participation criteria and map of study locations
respiratory-icon

Key Participation Requirements

Gender
Female, Male
Age group
Adult
Age Range
18 Years to 50 Years
Trial Duration
May 8, 2017 - May 24, 2017
Phase
Phase 4

Study Type

Interventional